Panobacumab
- CAS No.
- 885053-97-4
- Chemical Name:
- Panobacumab
- Synonyms
- Panobacumab;Research Grade Panobacumab;Research Grade Panobacumab(DXX02101)
- CBNumber:
- CB98080784
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
- TDS File:
- TDS
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | 62B4OXU259 |
Panobacumab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0612950 | Panobacumab 98.24% | 885053-97-4 | 1mg | $282 | 2026-06-04 | Buy |
| ChemScene | CS-0612950 | Panobacumab 98.24% | 885053-97-4 | 5mg | $737 | 2026-06-04 | Buy |
| ChemScene | CS-0612950 | Panobacumab 98.24% | 885053-97-4 | 10mg | $1170 | 2026-06-04 | Buy |
| ApexBio Technology | BA1454 | Panobacumab | 885053-97-4 | 1mg | $234 | 2026-05-06 | Buy |
| ApexBio Technology | BA1454 | Panobacumab | 885053-97-4 | 5mg | $612 | 2026-05-06 | Buy |
Panobacumab Chemical Properties, Uses, Production
Uses
Panobacumab (KBPA101) is a fully human IgM/κ monoclonal antibody generated by immortalizing human B lymphocytes against the LPS O polysaccharide of serotype O11 of P. aeruginosa[1].
in vivo
Panobacumab (KBPA101) (1-4 mg/kg; i.v.; once) protects mice from systemic infection with P. aeruginosa serotype O11 in a murine burn wound model[1].
Panobacumab (KBPA101) (0.005-0.4 mg/kg; i.v.; once) protects mice from local lung infection with P. aeruginosa serotype O11 in an acute lung infection model[1].
| Animal Model: | Female NMRI mice, murine burn wound model[1] |
| Dosage: | 1, 2, or 4 mg/kg |
| Administration: | Intravenous injection, single dose |
| Result: | Significantly reduced mortality compared to untreated control animals administered either immediately or 4 h postchallenge. |
| Animal Model: | BALB/c mice, acute lung infection model[1] |
| Dosage: | 0.005 to 0.4 mg/kg |
| Administration: | Intravenous injection, single dose |
| Result: | Led to rapid clearance of P. aeruginosa from the lung, completely cleared systemic P. aeruginosa from the spleen, whereas live bacteria were still present in untreated mice at 48 h postchallenge, showed milder macroscopic lung pathology at 6 and 24 h after infection. |
References
[1] Horn MP, et al. Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11. Antimicrob Agents Chemother. 2010 Jun;54(6):2338-44. DOI:10.1128/AAC.01142-09
Panobacumab Preparation Products And Raw materials
Raw materials
Preparation Products
Panobacumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| BOC Sciences | 1-631-485-4226; 16314854226 | info@bocsci.com | United States | 9920 | 65 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1577 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10305 | 58 |
| Beijing Jin Ming Biotechnology Co., Ltd. | 010-60605840 | psaitong@jm-bio.com | China | 27626 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9864 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 7283 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11963 | 58 |
| Wuhan Acumen Bio-Technology Co.,ltd | 027-027-16602739303 16602739303 | 673003916@qq.com | China | 4593 | 58 |
| Changsha Fuzhen Biotechnology Co.，LTD | 15111215862 18229892877 | 3062105966@qq.com | China | 5550 | 58 |
